FDAsafety guidance66% confidence
Clinical Outcome Assessments (COA) Qualification Program Submissions
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Takeda; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Neurology · ADHD
- Sub-indication
- General
Related signal: FDA Submission Update for Adderall XR 10 by Takeda